Jardiance Vs. Steglatro: Drug Comparison

Jardiance^® (empagliflozin) is an oral medication used to improve blood sugar control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, as an adjunct to diet and exercise. It is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Additionally, Jardiance helps reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. It is also used to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. This medication works as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promoting the excretion of glucose through the urine​.

Steglatro^® (ertugliflozin) is an oral medication used to improve blood sugar control in adults with type 2 diabetes by inhibiting sodium-glucose co-transporter 2 (SGLT2), which reduces the reabsorption of glucose in the kidneys and increases glucose excretion through urine. Its FDA-approved indication is for the treatment of type 2 diabetes, typically alongside diet and exercise. Steglatro is available in tablet form, taken once daily. Common side effects include urinary tract infections, genital yeast infections, and increased urination, and it can also lead to dehydration or low blood pressure in some patients. Caution is advised for patients with kidney disease or those at risk for diabetic ketoacidosis.

Sodium-glucose co-transporter 2 (SGLT2) inhibitor

Sodium glucose co-transporter 2 (SGLT2) inhibitor

Jardiance (empagliflozin) is indicated:

• To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure

• To reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression

• To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease

• As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus

Steglatro (ertugliflozin) is indicated:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

• Typically taken orally once daily

• Comes in 10 mg and 25 mg tablets

• Typically taken orally once daily

• Comes in 5 mg and 15 mg tablets

Most common adverse reactions (5% or greater incidence) were:

• Urinary tract infections

• Female genital fungal infections

Most common adverse reactions (incidence ≥5%) were:

• Female genital fungal infections

• Hypersensitivity to empagliflozin or any of the excipients in Jardiance

• See the Full Prescribing Information for information on drug interactions and interference of Jardiance with laboratory tests

• Hypersensitivity to ertugliflozin or any of the excipients in Steglatro

• See the Full Prescribing Information for information on drug interactions and interference of Steglatro with laboratory tests

• Diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis

• Volume depletion

• Urosepsis and pyelonephritis

• Low blood sugar

• Necrotizing fasciitis of the perineum (Fournier's gangrene)

• Genital fungal infections

• Lower limb amputation

• Hypersensitivity reactions

• Pregnancy: Potential risk to a fetus especially during the second and third trimesters

• Breastfeeding: Not recommended when breastfeeding

• Diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis

• Lower limb amputation

• Volume depletion

• Urosepsis and pyelonephritis

• Low blood sugar

• Necrotizing fasciitis of the perineum (Fournier's gangrene)

• Genital fungal infections

• Pregnancy: Advise females of the potential risk to a fetus especially during the second and third trimesters

• Breastfeeding: Breastfeeding not recommended

*This information is from the label for brand name Jardiance^®. See the Full Prescribing Information for more complete information.

*This information is from the label for brand name Steglatro^®. See the Full Prescribing Information for more complete information.